# To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension

> **NCT07191899** · PHASE1 · RECRUITING · sponsor: **Suzhou Alphamab Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** KN060
- **DRUG:** 0.9% Sodium Chloride Injection

## Key facts

- **NCT ID:** NCT07191899
- **Lead sponsor:** Suzhou Alphamab Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-05
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07191899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07191899, "To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07191899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*